Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients

Abstract

The clinical characteristics of lung cancer in patients with idiopathic pulmonary fibrosis (IPF) differ from those of lung cancer in patients without IPF. Thus, we aimed to evaluate the impact of IPF on the clinical course of patients with lung cancer. Clinical data of IPF patients with lung cancer (n = 122) were compared with those of patients with lung cancer without IPF (n = 488) matched by age, sex, histopathology, stage, and date of diagnosis of lung cancer. The median follow-up period after diagnosis of lung cancer was 16 months. Among patients with IPF, the mean age was 68 years, 95.9% were male, 93.2% were ever-smokers, and squamous cell carcinoma was the most common cancer type (48.4%). The IPF group had poorer lung function and lower lobe predominance of lung cancer than the no-IPF group. The IPF group showed a poorer prognosis than the no-IPF group (5-year survival rate: 14.5% vs. 30.1%, respectively; P < 0.001), even after adjusting for lung function and regardless of the treatment method. Among patients with IPF, 16.8% experienced acute exacerbation within 1 month after treatment of lung cancer. The treatment outcome of patients with lung cancer and IPF was generally unfavorable, and acute exacerbation triggered by treatment frequently occurred.

Figure 1

Comparison of survival curves between the IPF and no-IPF groups among patients with lung cancer. (A) Total lung cancer, (B) adenocarcinoma, (C) squamous cell carcinoma, and (D) small cell lung cancer.

Figure 2

Comparison of survival curves between the IPF and no-IPF groups among patients with lung cancer. (A) NSCLC stage I, (B) NSCLC stage II, (C) NSCLC stage III, (D) NSCLC stage IV, (E) SCLC limited stage, and (F) SCLC extensive stage. NSCLC non-small cell lung cancer, SCLC small cell lung cancer.